TITLE

ROCHE/GLYCART TO DISCOVER NEW THERAPEUTIC ANTIBODIES

PUB. DATE
November 2004
SOURCE
Worldwide Biotech;Nov2004, Vol. 16 Issue 11, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the agreement between Roche and GLYCART to discover next-generation therapeutic antibodies using GlycoMabTM technology. Terms of the agreement; Factors that influenced Roche to license GlycoMabTM; Profile of GLYCART and Roche; Information on GlycoMab.
ACCESSION #
14884366

 

Related Articles

  • Genentech, GlycArt and Roche sign collaboration agreement.  // PharmaWatch: Cancer;Nov2008, Vol. 7 Issue 11, p4 

    The article reports on the collaboration agreement among biotechnology company Genentech Inc., GlycArt company, and Roche Group Co.. It states that the firms plans to develop GA101, a humanized anti-CD20 monoclonal antibody that will potentially treat hematological malignancies. According to Hal...

  • Roche: buying up for biotech boost.  // PharmaWatch: Biotechnology;Sep2005, Vol. 4 Issue 9, p14 

    The article report that Roche Holding AG has announced that it will acquire GlycArt Biotechnology AG for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology markets. The deal promises to strengthen Roche's drug...

  • Adimab Yeast-Based Platform Draws Big Pharma's Attention. Hollingsworth, Catherine // BioWorld Today;6/22/2009, Vol. 20 Issue 118, p1 

    This article reveals that Adimab Inc. has successfully secured two major drug discovery deals in June 2009. In addition, the company is involved in negotiations with several major drugmakers for possible collaborations in the future. Particular focus is gievn to the company's business model....

  • FINE CHEMICALS. Tyler, Alan // European Chemical News;10/4/2004, Vol. 81 Issue 2118, p28 

    Presents news briefs on the fine chemical industry as of October 4, 2004. License agreement between U.S.-based biotechnology company Kereos and DowPharma; Information on a joint venture company to be established in China by Mitsubishi Corp. with Junsei Chemical and a Shanghai-based fine...

  • Roche In-Licenses Galaxy Biotech's Preclinical FGF2 Antibody Programme. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 10, p130 

    The article reports that Roche has licensed international rights to the preclinical-stage antibodies of Galaxy Biotech targeting fibroblast growth factor 2 (FGF2) in cancer metastasis. It states that Roche will be responsible for the development and commercialisation of the project and will pay...

  • Roche-Kosan case study.  // Roche-Kosan Case Study: Successful Early Licensing Strategies;Oct2005, p1 

    Presents a case study of the licensing partnership between Kosan Biosciences and Roche. Background of the companies; Principles of win-win partnership; Relevance of the establishment of a common research and development and clinical management team to the company.

  • Roche Selects 12 Potential Manufacturing Partners for Tamiflu. Rios, Maribel // Pharmaceutical Technology;Feb2006, Vol. 30 Issue 2, p20 

    The article reports on the selection of Roche Pharmaceuticals for 12 potential manufacturing partners to enhance the global supply of its Tamiflu neuromanidase inhibitor in the U.S. Roche choose the 12 from nearly 200 manufacturers who wanted to take part in the Global Tamiflu Supply Network....

  • ROCHE SELECTS TWO GENMAB ANTIBODIES AS CLINICAL CANDIDATES.  // Worldwide Biotech;May2004, Vol. 16 Issue 5, p1 

    Reports on the decision of Roche to select Genmab antibodies as candidates for clinical development. Terms of agreement between Roche and Ganmab AS; Value of Genmab and Roche collaboration; Background of Genmab.

  • Roche chooses to develop Genmab antibodies.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p8 

    Focuses on the selection of two Genmab AS antibodies by Roche as candidates for clinical development. Terms of the agreement; Production of antibody product candidates; Effectivity of the development of antibodies.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics